Incorporating Specialist Independent Prescribing Pharmacist (SIPP) sessions into the Movement Disorder Service
Objective: To describe the incorporation of a prescribing pharmacist into a Multi-disciplinary Parkinson's clinic based in a University Hospital Background: Evidence shows that a multidisciplinary…Implementation and Validation of a Biometric Solution for Remote Monitoring of Motor Symptoms in Patients with Huntington Disease in a Phase II Clinical Trial
Objective: To implement and validate quantification of motor dysfunction in a Huntington disease (HD) clinical trial using machine learning algorithmic analysis derived from biometric monitoring…The impact of gastric acid suppressants and antacids on levodopa plasma concentration in patients with Parkinson’s disease
Objective: The levodopa tablet is prone to dissolve in acidic conditions. We investigated whether gastric acid suppressants (histamine-2 receptor antagonists or proton pump inhibitors) and…Efficacy, Safety, and Tolerability of Pridopidine in Huntington Disease (HD): Results From the Phase II Dose-Ranging Study, Pride-HD
Objective: To assess efficacy, safety, and tolerability of multiple doses of pridopidine in HD patients (pts) with signs of motor dysfunction. Background: Prior trials suggested…Subthalamic Nucleus Deep Brain Stimulation in Early Stage Parkinson’s Disease Reduces the Risk of Polypharmacy: Five-Year Analysis
Objective: To compare the proportion of subjects on polypharmacy after five years in the deep brain stimulation (DBS) in early stage Parkinson’s disease (PD) pilot…Disease-modification in Translational Models of Parkinson’s disease by the Rho Kinase Inhibitor Fasudil
Objective: To evaluate the therapeutic potential of the Rho Kinase (ROCK) inhibitor Fasudil in translational models of Parkinson’s disease (PD). Background: There is still a…Medical Treatment Termination in Parkinson’s Disease Patients after Hepad Therapy: A Case Series
Objective: To report seven clinical cases of treatment completion and improvement of symptoms after a PD therapy regimen that included Hepad. Background: DOPA decarboxylase inhibitor…The influence of neurorehabilitation on Parkinson medication
Objective: To investigate the influence of neurorehabilitation on the dose changes of Parkinson medication over time. Background: In progressive disorders such as Parkinson’s disease (PD),…Conversion to IPX066, extended-release carbidopa-levodopa, in advanced Parkinson’s disease patients: Dosing patterns
Objective: Describe the dosing patterns in advanced Parkinson's disease (PD) patients who completed conversion to IPX066 from other levodopa formulations. Background: IPX066 is an extended-release…Critical path for Parkinson’s II: Global regulatory agencies support the use of dopamine transporter neuroimaging as an enrichment biomarker to enable clinical trials in early Parkinson’s disease
Objective: This presentation focuses on neuroimaging of the Dopamine Transporter as an enrichment biomarker in clinical trials of Parkinson's disease (PD). Background: The Critical Path…
- « Previous Page
- 1
- …
- 29
- 30
- 31
- 32
- 33
- 34
- Next Page »